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Abstract
Background: Our aim was to investigate the aortic distensibility (AD) of the ascending aorta and carotid artery
intima-media thickness (c-IMT) in HIV-infected patients compared to healthy controls.
Methods: One hundred and five HIV-infected patients (86 males [82%], mean age 41 ± 0.92 years), and 124 age and
sex matched HIV-1 uninfected controls (104 males [84%], mean age 39.2 ± 1.03 years) were evaluated by
high-resolution ultrasonography to determine AD and c-IMT. For all patients and controls clinical and laboratory
factors associated with atherosclerosis were recorded.
Results: HIV- infected patients had reduced AD compared to controls: 2.2 ± 0.01 vs. 2.62 ± 0.01 10-6 cm2 dyn-1,
respectively (p < 0.001). No difference was found in c-IMT between the two groups. In multiadjusted analysis, HIV
infection was independently associated with decreased distensibility (beta –0.45, p < 0.001). Analysis among
HIV-infected patients showed that patients exposed to HAART had decreased AD compared to HAART-naïve
patients [mean (SD): 2.18(0.02) vs. 2.28(0.03) 10-6 cm2 dyn-1, p = 0.01]. In multiadjusted analysis, increasing age and
exposure to HAART were independently associated with decreased AD.
Conclusion: HIV infection is independently associated with decreased distensibility of the ascending aorta, a marker
of subclinical atherosclerosis. Increasing age and duration of exposure to HAART are factors further contributing to
decreased AD.
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Background
The use of highly active antiretroviral therapy (HAART)
resulted in a significant decrease in morbidity and mor-
tality in patients with human immunodeficiency virus
(HIV) infection [1], turning this lethal infection to a
chronic ambulatory disease. However, the initial opti-
mism has been tempered when it became evident that
HAART has metabolic side effects such as fat redistribu-
tion, dyslipidemia, insulin resistance, glucose intolerance,
metabolic syndrome, and overt diabetes; all of them are
established risk factors for atherosclerosis and cardiovas-
cular disease [2-5]. Indeed, soon after the introduction
of HAART into the clinical practice, researchers
reported unexpected vascular events among young
patients. A large prospective study confirmed that
HAART, especially the protease inhibitor (PI)–contain-
ing regimens, increases the risk for cardio- and cerebro-
vascular events in HIV-infected persons [6]. This finding
suggests that HAART causes early atherosclerosis [7,8].
The observed excess cardiovascular risk cannot be
attributed solely to the side effects of antiretroviral drugs
since chronic HIV infection itself has a role, as it has
been shown for other chronic inflammatory diseases [9].
Moreover, HAART increased life expectancy and as HIV
seropositive population ages, chronic diseases like ath-
erosclerotic cardiovascular disease become increasingly
important [10,11].
It is difficult to dissect relative contributions of con-
ventional cardiovascular risk factors, metabolic side
effects of antiretroviral drugs, and HIV infection itself
on early atherosclerosis and cardiovascular events, as
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these factors frequently co-exist in the same patient.
Moreover, studies using clinical endpoints to investigate
cardiovascular outcomes in patients with HIV infection,
who typically are young or middle-aged, need large
numbers of patients because of the low event rate.
Therefore, studies using surrogate markers for early ath-
erosclerosis are required.
Researchers have reported that the reduction of the
elastic properties of aorta represents an early stage in
the atherosclerotic process [12-16]. Aortic distensibility
(AD) is an elasticity index of the ascending aorta, and
along with carotid artery intima-media thickness (c-
IMT) are simple and reproducible markers of subclinical
arteriosclerotic disease and have been identified as
strong predictors of cardiovascular mortality in different
clinical settings [17-24]. There are no studies for early
atherosclerosis of ascending aorta among HIV-infected
patients. The aim of this study was to investigate the dis-
tensibility of the ascending aorta and c-IMT in HIV-
infected patients compared with age and sex matched
uninfected controls, and to investigate whether HIV in-
fection itself, conventional risk factors for atheroscler-
osis, and/or HAART are associated with early
atherosclerosis.
Methods
We enrolled in the study a total of 105 consecutive,
HIV-infected patients attending the outpatient clinic of
the Athens Laikon Hospital. Controls were 124 healthy
volunteers recruited from hospital staff, as well as their
relatives or friends. HIV infection was ruled out in con-
trols by serologic testing with their consent. Control
subjects were individually matched with patients by age
(± 5 years) and sex.
Demographic and clinical data such as age, sex,
body weight, arterial blood pressure, and history of
smoking were obtained from all patients and control
subjects, as well as blood samples for laboratory mea-
surements, including blood count, glucose, total chol-
esterol, triglyceride, high density lipoprotein (HDL),
low-density-lipoprotein (LDL) and creatinine levels.
Hypertriglyceridemia and hypercholesterolemia were
defined as triglyceride and cholesterol level equal or
more than 150 and 200 mg/dl, respectively. Hyperten-
sion was defined as systolic and diastolic blood pres-
sure level above 140mmHg and 90mmHg, respectively.
Moreover, for each HIV-infected patient the following
information corresponding to the sampling time point
was recorded: risk group, disease duration, CDC stage,
CD4 cell count, viral load, and HAART. The study
was approved by the Institutional Review Board of the
Laikon General Hospital, Athens, Greece. All partici-
pants gave their informed consent.
All HIV-infected patients and seronegative controls
were evaluated to determine c-IMT and AD.
Visualization of the carotid artery was obtained via high
resolution, B-mode carotid artery ultaronography, and c-
IMT was measured by the same investigator. Measure-
ment of c-IMT was performed in the common carotid
artery, of both left and right side, 1cm proximal to ca-
rotid bulb and at least three separate measurements of
each side were obtained according to previous recom-
mendations [25]. Abnormal c-IMT was defined as a
value of equal or more than 0.9 mm. AD was deter-
mined noninvasively based on the relationship between
changes in aortic diameter and pressure with each car-
diac pulse [26,27]. The echocardiographic study was car-
ried out using a Hewlett Packard Sonos 1000 ultrasound
system (Hewlett Packard), using a 25-MHz transducer.
Each subject was placed in the mild left recumbent pos-
ition and the ascending aorta was recorded at a level 3
cm above the aortic valve in the M-mode tracings
guided by the two-dimensional echocardiogram in the
parasternal long axis view [26]. Internal aortic diameters
were measured by means of a caliper in systole and dia-
stole as the distance between the trailing edge of the an-
terior aortic wall and the leading edge of the posterior
aortic wall. Systolic aortic diameter was measured as the
maximal anterior motion of the aorta and diastolic
diameter at the peak of the QRS complex on the simul-
taneously recorded electrocardiogram. Ten consecutive
cardiac beats were measured routinely and averaged
[26,27]. Blood pressure was measured with a Dinamap
TM XL vital signs monitor (Johnson-Johnson, Arlington,
VA). AD was calculated according to the formula
[26,28]:
Aortic distensibility ¼ 2ΔD
Dd Ps Pdð Þ 10
6dyn1cm2
Where ΔD is the change of the aortic diameter be-
tween systole and diastole, Dd is the aortic diameter in
diastole, Ps is the systolic arterial blood pressure and Pd
is the diastolic arterial blood pressure. The cardiologist
who performed the measurements (IM) was blind of the
results of the autonomic function tests of the examined
subjects. The intraobserver and interobserver mean per-
centage error (absolute difference between two observa-
tions divided by the mean and expressed as percentage)
was determined for the aortic dimensions in 20 ran-
domly selected subjects and were 4.2% and 4.6% for the
systolic and 4.1% and 4.4% for the diastolic dimensions
in our centre, respectively.
Statistical analysis
STATA package v8 (Stata Corporation, College Station,
TX, USA) was used for data analysis. Continuous
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variables are presented as mean ± SD, and compared
using the t-test. Dichotomous variables are presented as
frequency (%) and compared using the chi-square test.
For HIV-infected patients vs. controls comparison, a
multiadjusted analysis for AD (dependent variable)
which was the major outcome was performed using the
linear regression technique and all significant variables
of the univariate analysis entered the model as inde-
pendent covariates.
In a second step, a univariate and multivariate linear
regression (using a stepwise, backward selection tech-
nique) were performed in HIV-positive group only to
identify influential factors for AD. A two-sided P-value
<0.05 was considered as statistically significant.
Results
Characteristics of the study population
The study population consisted of 105 HIV seropositive
patients (86 male [82%]) with mean age ± SD, 41 ± 0.92
years and 124 control subjects (104 male [84%] with
mean age 39.2 ± 1.03 years. Sixty out of the 105 HIV-
infected patients (57%) had acquired immunodeficiency
syndrome (AIDS) and 89 of them (85%) were receiving
HAART. Patients’ clinical characteristics are shown on
Table 1. The prevalence of dislipidemia was higher
among HIV-infected patients, as they had higher fasting
plasma concentrations of total cholesterol (p < 0.001),
triglycerides (p < 0.001) and LDL (p = 0.08) and lower
concentrations of HDL (p < 0.001), compared to HIV-
seronegative controls. On the contrary, the prevalence of
obesity [Body mass index (BMI) > 30 kg/m2] was signifi-
cantly higher in control subjects than in HIV-infected
patients (p < 0.001). The mean arterial pressure was
higher among controls regarding both systolic and dia-
stolic arterial pressure (p < 0.001); hypertension was sta-
tistically more frequent in controls than in HIV-infected
patients [13, (10.5%) vs. 1, (1%), respectively, p = 0.003]
(Table 2).
Table 1 Clinical data in HIV-infected patients
Patients characteristics N=105
AIDS, (%) 60 (57)
HAART, (%) 89 (85)
Disease duration (median/range, months) 81/1-246
CD4 (cells/μL) 519 ± 346
Viral load (copies/ml)
Median 80
Range 40 - 860000
Undetectable (%) 50 (48)
IV Drug abuse 3 (3)
Treatment with PIs, (%) 71 (68)
Treatment with NNRTIs, (%) 42 (40)
Treatment with NRTIs, (%) 87 (83)





AIDS, acquired immunodeficiency syndrome; HAART, highly active
antiretroviral treatment; PI, protease inhibitor; NNRTI, non-nucleoside reverse
transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; IV,
intravenous.
Data are given as mean ± standard deviation.
Table 2 Comparison of the two groups (Univariable
analysis)
Patients Controls P value
(N=105) (N=124)
Basic Demographics
Male sex, (%) 86 (82) 104 (84) 0.69
Age (years) 41.0 ± 0.92 39.2 ± 1.03 0.19
Greek origin, (%) 99 (94) 110 (89) 0.13
Metabolic profile
Obesity, (BMI > 30 kg/m2) 5 (4.8) 25 (20.2) 0.001
Diabetes, (%) 4 (3.8) 3 (2.5) 0.54
Glucose (mg dL−1) 93.5 ± 1.67 95.2 ± 2.13 0.55
Hypertriglyceridemia, (%) 64 (61) 36 (30) <0.001
Triglycerides (mg dL−1) 234.3 ± 19.5 118.5 ± 6.1 <0.001
Hypercholesterolemia, (%) 98 (93) 51 (41) <0.001
Total cholesterol (mg dL−1) 220.5 ± 5.84 195.8 ± 4.14 <0.001
LDL (mg dL−1) 135.1 ± 5.07 124.2 ± 3.59 0.08
HDL (mg dL−1) 41.9 ± 0.95 47.9 ± 1.20 <0.001
Smokers, (%) 47 (37.9) 59 (56.2) 0.36
History/Laboratory values
Coronary Artery Disease/Stroke, (%) 1 (1) 6 (4.8) 0.09
Arterial Hypertension, (%) 1 (1) 13 (10.5) 0.003
-systolic (mmHg) 117.7 ± 0.91 123.5 ± 1.03 <0.001
-diastolic (mmHg) 72.8 ± 0.63 77.9 ± 0.78 <0.001
Hb values (mg dL−1) 13.4 ± 0.17 14.2 ± 0.15 <0.001
Creatinine (mg dL−1) 0.95 ± 0.01 1.08 ± 0.02 <0.001
CRP (mg dL−1) 5.0 ± 0.78 9.4 ± 2.25 0.09
Cardiac Indexes
IMT right (mm) 0.59 ± 0.01 0.66 ± 0.08 0.41
IMT right ≥ 0.9mm 4(4) 9(7) 0.26
IMT left (mm) 0.62 ± 0.01 0.67 ± 0.08 0.59
IMT left ≥ 0.9mm 11(10) 9(7) 0.39
Distensibility (10-6 dyn-1 cm2) 2.20 ± 0.01 2.62 ± 0.01 <0.001
Data are given as mean ± standard deviation.
BMI, body mass index; LDL, low density lipoprotein; HDL, high density
lipoprotein; Hb, hemoglobin; CRP, C-reactive protein; IMT, Intima-media
thickness of carotid artery.
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Distensibility of the ascending aorta and HIV infection in
the whole study population
We first compared HIV-infected patients with controls
using t-test. AD was statistically lower in patients’ popu-
lation than in uninfected controls: 2.2 ± 0.01 vs.
2.62 ± 0.01 10-6 cm2 dyn-1, respectively (p < 0.001)
(Table 2). Nevertheless, no difference was found in c-
IMT between the two groups.
In multiadjusted analysis, after adjustment for all sig-
nificant confounders, HIV infection was independently
associated with decreased distensibility (beta –0.45,
p < 0.001) (Table 3). Other factors associated with
decreased AD were, as expected, obesity and increasing
diastolic pressure.
Distensibility of the ascending aorta in HIV-infected
patients
A separate analysis was performed within the group of
HIV-infected patients. Patients exposed to HAART had
decreased distensibility of the ascending aorta compared
to HAART-naïve patients [mean (SD): 2.18(0.02) vs. 2.28
(0.03), p = 0.01]. In multivariate linear regression analysis
only increasing age and cumulative duration of exposure
to HAART were independently associated with
decreased AD (Table 4). Based on the previous model,
Figure 1 shows the effect of HAART therapy on the dis-
tensibility of the ascending aorta, stratified for age > =40
years vs. <40 years.
Discussion
The main findings of our study were that HIV-infected
patients had significantly reduced distensibility of the
ascending aorta compared to age and sex matched con-
trol subjects. On the contrary, no difference in c-IMT
was observed between the two groups. Multiadjusted
analysis showed that after adjustment for conventional
cardiovascular risk factors HIV infection was independ-
ently associated with decreased AD. Among HIV-
infected patients, those exposed to HAART had
significantly decreased AD compared to HAART-naïve
patients. In multivariate analysis, increasing age and dur-
ation of HAART exposure were factors independently
associated with decreased AD. Moreover, the effect of
HAART on the distensibility was more pronounced
among patients older than 40 years old (Figure 1).
The reduced distensibility of the ascending aorta that
we found among HIV-infected patients compared to un-
infected controls is a marker of subclinical arterioscler-
otic disease and has been identified as a strong predictor
of cardiovascular mortality in different clinical settings
[17-21]. In a large population study, AD was inversely
related to conventional cardiovascular disease risk fac-
tors, such as older age, hypertension, smoking, and low
HDL-cholesterol levels [29]. In accordance, in our study
multiadjusted analysis showed that vascular risk factors
such as obesity, and increasing diastolic pressure were
also important for decreased distensibility of the ascend-
ing aorta. It is interesting that we found decreased dis-
tensibility among HIV-infected patients despite the fact
that obesity and blood pressure were significantly higher
among controls. One explanation could be that dislipide-
mia was statistically more frequent among HIV-infected
patients, due to the HAART side effects or to the
chronic infection per se.
Multi-adjusted analysis showed that after correction
for other vascular risk factors, HIV infection was inde-
pendently associated with decreased AD. In fact, prema-
ture atherosclerosis has been reported in young adults
with HIV infection in the pre–HAART era [30]. The
cardiovascular disease risk associated with HIV infection
appears to be partially attenuated by antiretroviral treat-
ment, since treatment interruption increases short-term
risk of cardiovascular disease events [11]. These findings
suggest that HIV infection itself may increase the risk
for cardiovascular disease, as it has been shown for other
chronic inflammatory diseases [9] in the non-HIV set-
ting. Many markers of inflammation are markedly ele-
vated in individuals with untreated HIV infection and
are only partially reversed by effective combination anti-
retroviral therapy [31].
Our data are consistent with previous studies showing
that HIV infection per se, as well as HAART is asso-
ciated with increased stiffness [30,32-36] of peripheral
arteries (femoral and branchial) and the carotid artery.
Interestingly, recent investigations have shown that bio-
logical and vascular age in HIV infected patients is
increased [37,38]. Our study did not find increased c-
IMT in HIV-infected patients compared to uninfected
Table 3 Multivariate* linear regression analysis: the
potential effect of various confounding factors on aortic
distensibility in the total study population (HIV-infected
persons and controls)
Beta coefficient P-value
Obesity (yes vs. no) -0.053 0.05
Triglycerides (mg/dl) -0.00006 0.36
Total Cholesterol (mg/dl) -0.0003 0.09
Systolic pressure (mm Hg) -0.002 0.08
Diastolic pressure (mm Hg) -0.003 0.03
Hb values (gr/dl) +0.008 0.13
Creatinine (mg/dl) +0.07 0.19
HIV seropositivity (yes vs. no) -0.45 <0.001
HIV, human immunodeficiency virus; Hb, hemoglobulin.
Beta coefficient expresses the mean difference in distensibility. Positive sign
corresponds to protective effect while minus sign to decreased distensibility.
*All the significant variables of Table 2 (with p<0.05) were included. When the
same characteristic was reported as both continuous and categorical, the
continuous variable was preferred, (e.g. cholesterol in mg/dl vs.
hypercholesterolemia).
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controls. Conflicting evidence exists in the bibliography
on the c-IMT: some studies reported increased c-IMT in
HIV- infected patients compared with HIV-negative
controls [30,33,39-44] but others did not [45-48]. It is
noteworthy that our HIV-infected population had
decreased distensibility of the ascending aorta and a nor-
mal c-IMT. This may imply that there are differences in
the effect of HIV along the arterial system and reduced
AD is an earlier marker of subclinical atherosclerosis
compared to c-IMT. An alternative explanation could be
that although arterial stiffening is thought to be a gener-
alized phenomenon, different arterial segments are
known to respond differently to atherosclerotic risk fac-
tors [49-51].
Our study showed that among HIV-infected patients,
increasing age and longer exposure to HAART contrib-
ute further to decreased distensibility of the ascending
aorta. Moreover, the effect of HAART on the AD was
more pronounced among patients older than 40 years
old. While increasing age is a well known risk for ath-
erosclerosis, the effect of HAART on accelerating ath-
erosclerosis remains controversial. Chronic HIV
infection may lead to vascular endothelial damage and
damage the elastic properties of an artery by sustaining a
low degree of inflammation [52]. HAART has beneficial
effects by reducing the inflammation due to active HIV
infection, and detrimental effects such as dyslipidemia.
Although it is difficult to determine the net effect in an
individual patient and in different arterial segments, a
recent study showed that endothelial dysfunction actu-
ally improved after start of HAART despite the rapid
onset of dyslipidemia [53]. Our study had not enough
statistical power to detect if PI containing regimens had
different effect on the AD compared to NNRTI-
containing regimens.
Our study has some limitations. Aortic diameters were
measured echocardiographically and not invasively. A
previous study has shown that aortic diameter can be
determined with a high degree of accuracy in subjects
whose cardiothoracic anatomy permits an echocardio-
graphic signal of satisfactory quality, and the values
obtained by echocardiography were not significantly dif-
ferent from those obtained by angiography [26]. In
addition, pulse pressure estimated non-invasively from
the brachial artery by external sphygmomanometry has
been used for the calculation of AD in previous reports
[26,54-56]. These non-invasive techniques have also
been used for calculating AD in previous studies [55-57].
Thus a reliable estimation of the elastic properties of the
ascending aorta using completely non-invasive techni-
ques is feasible. Another limitation was the very high
proportion of male subjects included in the cohort,
Table 4 Univariate & Multivariate* linear regression analysis: the potential effect of various confounding factors on
aortic distensibility in HIV-infected patients
Univariate Analyis Multivariate Analysis
Beta coefficient p Beta coefficient p
Age (per year) -0.007 <0.001 -0.006* <0.001
Female sex +0.04 0.20
Total Cholesterol -0.0002 0.27
Hemoglobin +0.01 0.44
CD4 (+) T-cell count +0.00007 0.07
Viral load (per 1000 copies increase) +0.00004 0.76
AIDS -0.04 0.15
HAART duration (months) -0.002 0.004 -0.001* 0.04
HAART (exposed vs. naïve) -0.1 0.01
HIV duration (months) -0.0005 0.02
HIV, human immunodeficiency virus; AIDS, acquired immunodeficiency syndrome; HAART, highly active anti-retroviral therapy.
Beta coefficient expresses the mean difference in distensibility. Positive sign corresponds to protective effect while minus sign to decreased distensibility.





















Figure 1 Effect of HAART therapy on the distensibility of
ascending aorta, stratified for age<=40 years vs. >40 years old
(fitted values).
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which could limit the generalization of results to female
HIV-infected patients. Moreover, the potential impact of
past/active drug abuse could not be reliably evaluated, as
only 3 patients (3%) had a history of drug abuse.
Conclusions
HIV infection is independently associated with
decreased distensibility of the ascending aorta, a marker
of premature atherosclerosis. This suggests that patients
with HIV infection may be at increased cardiovascular
disease risk, independent of the presence of classical car-
diovascular risk factors. Study of arterial elasticity as
early marker of vascular damage could be promising and
more appropriate investigation in HIV people than
evaluation of cIMT.
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